Enzene Biosciences Limited announced that it has received INR 4.08 billion in funding from Eight Roads Ventures, Impresa Management LLC, Alkem Laboratories Limited
January 28, 2023
Share
Enzene Biosciences Limited announced that it has received INR 4,080,000,000 in an equity funding on January 29, 2023. The transaction included participation from Eight Roads Ventures, Impresa Management LLC and Alkem Laboratories Limited.
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
Enzene Biosciences Limited announced that it has received INR 4.08 billion in funding from Eight Roads Ventures, Impresa Management LLC, Alkem Laboratories Limited
ALKEM LABORATORIES LIMITED 
